phentermine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
anorexics	2140	122-09-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: phentermine duromine normephentermine phentermine hydrochloride phentermine HCl phentermine resin complex	A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity. Molecular weight: 149.24 Formula: C10H15N CLOGP: 2.14 LIPINSKI: 0 HAC: 1 HDO: 1 TPSA: 26.02 ALOGS: -2.29 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

phentermine
duromine
normephentermine
phentermine hydrochloride
phentermine HCl
phentermine resin complex

A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.

Molecular weight: 149.24
Formula: C10H15N
CLOGP: 2.14
LIPINSKI: 0
HAC: 1
HDO: 1
TPSA: 26.02
ALOGS: -2.29
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
15	mg	O

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	4.19 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Hosey CM, Chan R, Benet LZ

Approvals:

Date	Agency	Company	Orphan
May 4, 1959	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cholecystitis chronic	170.08	17.22	58	6039	9611	50589416
Injury	87.69	17.22	61	6036	48864	50550163
Gallbladder disorder	75.69	17.22	38	6059	16704	50582323
Emotional distress	69.02	17.22	43	6054	28620	50570407
Anxiety	63.99	17.22	92	6005	177514	50421513
Phospholipidosis	61.54	17.22	10	6087	55	50598972
Carotid artery dissection	58.78	17.22	11	6086	150	50598877
Drug abuse	58.11	17.22	52	6045	59794	50539233
Arteriospasm coronary	54.33	17.22	19	6078	3383	50595644
Subarachnoid haemorrhage	47.35	17.22	24	6073	10752	50588275
Cholelithiasis	47.11	17.22	38	6059	37935	50561092
Psoriasis	44.60	17.22	48	6049	68952	50530075
Deep vein thrombosis	33.99	17.22	43	6054	73261	50525766
Encephalomalacia	32.03	17.22	8	6089	441	50598586
Spinal cord infarction	31.20	17.22	7	6090	242	50598785
Stress cardiomyopathy	27.35	17.22	15	6082	7872	50591155
Anhedonia	27.33	17.22	16	6081	9508	50589519
Biliary dyskinesia	25.14	17.22	10	6087	2540	50596487
Colitis ischaemic	24.78	17.22	15	6082	9468	50589559
Renal vein thrombosis	24.65	17.22	6	6091	297	50598730
Completed suicide	23.30	17.22	50	6047	131839	50467188
Depression	22.94	17.22	57	6040	165366	50433661
Device dislocation	21.44	17.22	19	6078	21527	50577500
Pseudomembranous colitis	20.95	17.22	9	6088	2776	50596251
Subacute cutaneous lupus erythematosus	19.48	17.22	8	6089	2207	50596820
Product dose omission issue	19.13	17.22	57	6040	183781	50415246
Medical device discomfort	18.02	17.22	7	6090	1670	50597357
Cholecystitis acute	17.95	17.22	11	6086	7095	50591932
Amyloidosis	17.67	17.22	6	6091	977	50598050
Pain	17.34	17.22	124	5973	578779	50020248
Pulmonary embolism	17.32	17.22	38	6059	101666	50497361

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	66.06	27.32	36	814	79847	29493830

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cholecystitis chronic	157.55	19.17	50	5532	9237	64483913
Drug abuse	95.28	19.17	84	5498	132290	64360860
Injury	88.59	19.17	57	5525	55935	64437215
Emotional distress	65.30	19.17	40	5542	35998	64457152
Gallbladder disorder	61.95	19.17	30	5552	17000	64476150
Phospholipidosis	57.77	19.17	10	5572	122	64493028
Arteriospasm coronary	55.40	19.17	20	5562	5445	64487705
Carotid artery dissection	54.40	19.17	11	5571	323	64492827
Anxiety	44.67	19.17	70	5512	202579	64290571
Psoriasis	44.64	19.17	42	5540	71661	64421489
Subarachnoid haemorrhage	42.70	19.17	24	5558	18414	64474736
Completed suicide	40.70	19.17	71	5511	224343	64268807
Deep vein thrombosis	39.39	19.17	47	5535	105135	64388015
Cholelithiasis	36.97	19.17	31	5551	45475	64447675
Stress cardiomyopathy	29.77	19.17	15	5567	9242	64483908
Pain	29.70	19.17	110	5472	553401	63939749
Spinal cord infarction	27.69	19.17	7	5575	567	64492583
Encephalomalacia	27.62	19.17	8	5574	1083	64492067
Product dose omission issue	25.86	19.17	54	5528	194693	64298457
Device dislocation	24.98	19.17	18	5564	21160	64471990
Colitis ischaemic	24.56	19.17	15	5567	13399	64479751
Renal vein thrombosis	24.17	19.17	6	5576	451	64492699
Respiratory arrest	22.02	19.17	25	5557	52960	64440190
Anhedonia	21.76	19.17	14	5568	13692	64479458
Biliary dyskinesia	21.51	19.17	8	5574	2364	64490786
Toxicity to various agents	20.92	19.17	74	5508	363439	64129711
Cardio-respiratory arrest	20.27	19.17	33	5549	98360	64394790
Subacute cutaneous lupus erythematosus	19.62	19.17	8	5574	3017	64490133

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A08AA01	ALIMENTARY TRACT AND METABOLISM ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS Centrally acting antiobesity products
FDA PE	N0000175372	Appetite Suppression
FDA EPC	N0000175423	Sympathomimetic Amine Anorectic
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D019440	Anti-Obesity Agents
MeSH PA	D001067	Appetite Depressants
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D000697	Central Nervous System Stimulants
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D013566	Sympathomimetics
CHEBI has role	CHEBI:35337	analeptic
CHEBI has role	CHEBI:35470	central nervous system agents
CHEBI has role	CHEBI:35524	sympathomimetic
CHEBI has role	CHEBI:37962	adrenergic agents
CHEBI has role	CHEBI:48560	dopaminergic agents
FDA PE	N0000175651	Increased Sympathetic Activity

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Low blood pressure	indication	45007003
Obesity	indication	414916001	DOID:9970
Hypotension Secondary to Spinal Anesthesia	indication
Prevention of Hypotension During Spinal Anesthesia	indication
Heart valve disorder	contraindication	368009	DOID:4079
Alcoholism	contraindication	7200002
Glaucoma	contraindication	23986001	DOID:1686
Feeling agitated	contraindication	24199005
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Mild pre-eclampsia	contraindication	41114007
Conduction disorder of the heart	contraindication	44808001
Diabetes mellitus type 1	contraindication	46635009	DOID:9744
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Pulmonary hypertension	contraindication	70995007	DOID:6432
Secondary glaucoma	contraindication	95717004
Angina pectoris	contraindication	194828000
Edema	contraindication	267038008
Syncope	contraindication	271594007
Arteriosclerosis obliterans	contraindication	361133006	DOID:5160
Hypertensive urgency	contraindication	443482000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.92	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 11.25MG BASE;69MG	QSYMIA	VIVUS	N022580	July 17, 2012	RX	CAPSULE, EXTENDED RELEASE	ORAL	8895057	June 9, 2028	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
EQ 11.25MG BASE;69MG	QSYMIA	VIVUS	N022580	July 17, 2012	RX	CAPSULE, EXTENDED RELEASE	ORAL	9011906	June 9, 2028	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
EQ 15MG BASE;92MG	QSYMIA	VIVUS	N022580	July 17, 2012	RX	CAPSULE, EXTENDED RELEASE	ORAL	8895057	June 9, 2028	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
EQ 15MG BASE;92MG	QSYMIA	VIVUS	N022580	July 17, 2012	RX	CAPSULE, EXTENDED RELEASE	ORAL	9011906	June 9, 2028	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
EQ 3.75MG BASE;23MG	QSYMIA	VIVUS	N022580	July 17, 2012	RX	CAPSULE, EXTENDED RELEASE	ORAL	8895057	June 9, 2028	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
EQ 3.75MG BASE;23MG	QSYMIA	VIVUS	N022580	July 17, 2012	RX	CAPSULE, EXTENDED RELEASE	ORAL	9011906	June 9, 2028	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
EQ 7.5MG BASE;46MG	QSYMIA	VIVUS	N022580	July 17, 2012	RX	CAPSULE, EXTENDED RELEASE	ORAL	8895057	June 9, 2028	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
EQ 7.5MG BASE;46MG	QSYMIA	VIVUS	N022580	July 17, 2012	RX	CAPSULE, EXTENDED RELEASE	ORAL	9011906	June 9, 2028	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
EQ 11.25MG BASE;69MG	QSYMIA	VIVUS	N022580	July 17, 2012	RX	CAPSULE, EXTENDED RELEASE	ORAL	8580299	June 14, 2029	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
EQ 15MG BASE;92MG	QSYMIA	VIVUS	N022580	July 17, 2012	RX	CAPSULE, EXTENDED RELEASE	ORAL	8580299	June 14, 2029	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
EQ 3.75MG BASE;23MG	QSYMIA	VIVUS	N022580	July 17, 2012	RX	CAPSULE, EXTENDED RELEASE	ORAL	8580299	June 14, 2029	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT
EQ 7.5MG BASE;46MG	QSYMIA	VIVUS	N022580	July 17, 2012	RX	CAPSULE, EXTENDED RELEASE	ORAL	8580299	June 14, 2029	USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR				WOMBAT-PK	CHEMBL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.80		WOMBAT-PK

External reference:

ID	Source
4019891	VUID
N0000147976	NUI
D05458	KEGG_DRUG
1197-21-3	SECONDARY_CAS_RN
4018166	VANDF
4018167	VANDF
4019891	VANDF
C0031447	UMLSCUI
CHEBI:8080	CHEBI
CHEMBL1574	ChEMBL_ID
DB00191	DRUGBANK_ID
CHEMBL1200912	ChEMBL_ID
D010645	MESH_DESCRIPTOR_UI
4771	PUBCHEM_CID
1064	INN_ID
7269	IUPHAR_LIGAND_ID
C045TQL4WP	UNII
221138	RXNORM
1294	MMSL
41147	MMSL
5278	MMSL
5279	MMSL
d00806	MMSL
001864	NDDF
001865	NDDF
001866	NDDF
373343009	SNOMEDCT_US
426428004	SNOMEDCT_US
53480001	SNOMEDCT_US
6394006	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
phentermine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0644	CAPSULE	15 mg	ORAL	ANDA	29 sections
phentermine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0647	CAPSULE	30 mg	ORAL	ANDA	29 sections
phentermine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0185-5000	CAPSULE	30 mg	ORAL	ANDA	29 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-0597	CAPSULE	30 mg	ORAL	ANDA	26 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1308	CAPSULE	30 mg	ORAL	ANDA	26 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1310	CAPSULE	30 mg	ORAL	ANDA	26 sections
Phentermine ResinER	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1366	CAPSULE, EXTENDED RELEASE	30 mg	ORAL	ANDA	26 sections
Phentermine ResinER	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1398	CAPSULE, EXTENDED RELEASE	15 mg	ORAL	ANDA	26 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1438	CAPSULE	30 mg	ORAL	ANDA	26 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1445	TABLET	37.50 mg	ORAL	ANDA	26 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1742	CAPSULE	15 mg	ORAL	ANDA	26 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1743	CAPSULE	37.50 mg	ORAL	ANDA	26 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-098	CAPSULE	30 mg	ORAL	ANDA	26 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-099	CAPSULE	15 mg	ORAL	ANDA	9 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-116	TABLET	37.50 mg	ORAL	ANDA	9 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-552	TABLET	30 mg	ORAL	ANDA	31 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-592	CAPSULE	37.50 mg	ORAL	ANDA	9 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-593	CAPSULE	30 mg	ORAL	ANDA	19 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-602	TABLET	37.50 mg	ORAL	ANDA	19 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10544-620	CAPSULE	30 mg	ORAL	ANDA	9 sections
LOMAIRA	HUMAN PRESCRIPTION DRUG LABEL	1	10702-001	TABLET	8 mg	ORAL	ANDA	17 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10702-025	TABLET	37.50 mg	ORAL	ANDA	25 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10702-026	CAPSULE	15 mg	ORAL	ANDA	29 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10702-027	CAPSULE	30 mg	ORAL	ANDA	29 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10702-028	CAPSULE	30 mg	ORAL	ANDA	29 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10702-029	CAPSULE	37.50 mg	ORAL	ANDA	25 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10702-067	TABLET	8 mg	ORAL	ANDA	17 sections
Phentermine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	11534-157	CAPSULE	15 mg	ORAL	ANDA	28 sections
Phentermine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	11534-159	CAPSULE	37.50 mg	ORAL	ANDA	29 sections
Phentermine hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	11534-160	TABLET	37.50 mg	ORAL	ANDA	29 sections